Lorus
Therapeutics To Present At Rodman & Renshaw
10th Annual
Healthcare Conference
November
10 - 12, 2008
-
Presentation available by web cast -
TORONTO, CANADA - November 11,
2008 - Lorus Therapeutics Inc. (“Lorus”), a biopharmaceutical company
specializing in the research and development of pharmaceutical products and
technologies for the management of cancer, today announced that Dr. Aiping
Young, President and CEO of Lorus, is invited to present a Company update at the
Rodman and Renshaw 10th Annual
Healthcare Conference being held at the New York Palace Hotel, New
York.
|
|
WHERE:
|
|
New
York Palace Hotel,
|
|
|
|
|
Kennedy
1, 4th
Floor
|
|
|
|
|
455
Madison Avenue at 50th
Street
|
|
|
|
|
New
York, NY
|
|
|
WHEN:
|
|
November
12, 2008
|
|
|
TIME:
|
|
11:35
a.m. EST (Eastern Standard Time)
|
Interested
parties may gain access to a live audio webcast of Dr. Young’s presentation by
visiting the Investor Relations section of Lorus' website at http://www.wsw.com/webcast/rrshq14/lrp,
which will be available on November 12, 2008.
This
conference provides informational service and networking opportunities for
healthcare companies and investors.
About Lorus
Lorus
is a biopharmaceutical company focused on the research and development of novel
therapeutics in cancer. Lorus’ goal is to capitalize on its research,
preclinical, clinical and regulatory expertise by developing new drug candidates
that can be used, either alone, or in combination with other drugs, to
successfully manage cancer. Through its own discovery efforts and an
acquisition and in-licensing program, Lorus is building a portfolio of promising
anticancer drugs. Lorus Therapeutics Inc. is listed on the Toronto
Stock Exchange under the symbol LOR.
Forward
Looking Statements
This
press release contains forward-looking statements within the meaning of Canadian
and U.S. securities laws. Such statements include, but are not limited to,
statements relating to: financings and corporate reorganizations, the
establishment of corporate alliances, the Company’s plans, objectives,
expectations and intentions and other statements including words such as
“continue”, “expect”, “intend”, “will”, “should”, “would”, “may”, and other
similar expressions. Such statements reflect our current views with
respect to future events and are subject to risks and uncertainties and are
necessarily based upon a number of estimates and assumptions that, while
considered reasonable by us are inherently subject to significant business,
economic, competitive, political and social uncertainties and
contingencies. Such expressed or implied forward looking statements
could include, among others: our ability to continue as a going concern, our
ability to repay or refinance the convertible debentures by October 2009; our
ability to obtain the capital required for research and operations; the inherent
risks in early stage drug development including demonstrating efficacy;
development time/cost and the regulatory approval process; the progress of our
clinical trials; our ability to find and enter into agreements with potential
partners; our ability to attract and retain key personnel; changing market
conditions; and other risks detailed from time-to-time in our ongoing quarterly
filings, annual information forms, annual reports and annual filings with
Canadian securities regulators and the United States Securities and Exchange
Commission.
Should
one or more of these risks or uncertainties materialize, or should the
assumptions set out in the section entitled “Risk Factors” in our filings with
Canadian securities regulators and the United States Securities and Exchange
Commission underlying those forward-looking statements prove incorrect, actual
results may vary materially from those described herein. These
forward-looking statements are made as of the date of this press release and we
do not intend, and do not assume any obligation, to update these forward-looking
statements, except as required by law. We cannot assure you that such
statements will prove to be accurate as actual results and future events could
differ materially from those anticipated in such
statements. Investors are cautioned that forward-looking statements
are not guarantees of future performance and accordingly investors are cautioned
not to put undue reliance on forward-looking statements due to the inherent
uncertainty therein.
Lorus
Therapeutics Inc.’s recent press releases are available through its website at
www.lorusthera.com. For Lorus' regulatory filings on SEDAR,
please go to www.Sedar.com. For SEDAR filings prior to July 10, 2007
you will find these under the company profile for Global Summit Real Estate Inc.
(Old Lorus).
For
further information, please contact:
Lorus
Therapeutics Inc.
Dr.
Saeid Babaei, 1-416-798-1200 ext. 490
ir@lorusthera.com
